Emergent BioSolutions Inc.: Emergent BioSolutions to Participate in First Quarter 2016 Investor Conferences

Tickers: EBS
, (GLOBE NEWSWIRE) -- (NYSE:EBS) announced today that a member of the company's senior management team will participate in the following investor conferences during the first quarter of 2016.

  • 34 Annual


    Presentation: - Eastern
  • Wells Fargo Specialty and Generic Drug Summit


    Presentation time TBD


  • Presentation day and time TBD
  • Annual


    Presentation day and time TBD
Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under 'Investors' as this information becomes available.

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About
is a global specialty biopharmaceutical company dedicated to one simple mission-to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at www.emergentbiosolutions.com.

Follow us on twitter: @emergentbiosolu.

Investor Contact:

Vice President, Investor Relations
240-631-3280
BurrowsR@ebsi.com

Media Contact:

Vice President, Global Public Affairs
and Corporate Responsibility
240-631-3394
SchmittT@ebsi.com

Emergent BioSolutions Inc. issued this content on 2015-12-21 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 2015-12-21 21:22:04 UTC

Original Document: http://investors.emergentbiosolutions.com/phoenix.zhtml?c=202582&p=irol-newsArticle&ID=2124503